Index

A
abbreviated new drug application (ANDA) pathway 7
Abreva
direct-to-OTC 31
innovation for 152
prescription market equity 19
safety and efficacy data for 44
active and implantable medical devices. See also devices
actual use studies (AUS) 9
FDA requirement for 43
Oxytrol for Women 107
Prilosec OTC 70, 74
primary behavioral measures in 43
adapalene gel. See Differin Gel (adapalene)
switch
adjudication process (mitigation) 108
Advil
approved by NDAs 23
brand equity 14
retail value of 20
Advisory Committee (ADCOM) meetings
Differin (adapalene) Gel meeting 131, 133
first-in-class Rx-to-OTC switches 31
first-in-class switches 77
for intranasal steroid switch 137
for OTC statins 87
for Plan B 52, 55
for Singulair 42
in switch process 35, 46, 91
lovastatin switch 84
Mevacor summary 90
Oxytrol 115–117
Pravachol switch 84
pravastatin hearing 86
Prilosec OTC 63, 67, 68, 71, 75
Questran (cholestyramine) switch 82
switch votes by 47
age-based distinction for marketing product 58
allergy Rx-to-OTC switches
brands launched 17. See also intranasal steroids (INS) switch
sales volume from switch 16, 17
Singulair Allergy enhanced DFL warning 42
switch effects for 13
antismoking products. See nicotine replacement therapy (NRT)
approval pathways for switch
centralized process in EU/RoW 162
decentralized procedure in EU/RoW 162
development of 8
full vs. partial switch 34
monograph process 32
new or supplemental NDA 31
Australia
asthma inhalers in 163
pharmacist-only medications in 163
switch process 163
B
brand equity value
consumer benefits in building 19
Nexium 24HR 19
patent expiration effects on 20
Rx brand trademark in switch 19
C
Center for Drug Evaluation and Research (CDER) review divisions 34
China
combined oral contraceptive (COC) 174
switch process 163
cholesterol management. See lipid management switch
Cialis (tadalafil)
commercial value of switch 18
partnering for switch 27
Claritin
new indication for 23
retail sales of 20
clinical trials 9. See actual use studies (AUS)
combination product regulatory pathways. See also constituent parts
consumer behavior studies
actual use studies 9–11
  Ome-MG 70
execution of 124–130
for support of switch 8–11
human factors studies 9–11
issues addressed 181
label comprehension studies 8–11
self-selection studies 8–11
Consumer Healthcare Products Association (CHPA)
public health benefits of switch 13–29
survey on role of OTC drugs 1, 4
consumer unmet need
erectile dysfunction treatment 170
Oxytrol 17
Plan B (levonorgestrel) case study 51
Prilosec OTC 65
Questran (cholestyramine) 83
Consumer Use Study of Over-the-Counter Mevacor (CUSTOM) 87
controlled access 51
Controloc 162
Convenient Access Responsible Education (CARE) 59

data exclusivity with Rx-to-OTC switch 7
Denmark 165, 166
Differin Gel (adapalene) switch 44, 121
Advisory Committee meeting and preparation 131

consumer behavior studies
actual use study 126–127
label comprehension study 125
targeted self-selection study 128
DFL comparison with representative acne product 124
FDA review 130–131
history of adapalene 122–123
indications for switch 121–123
initial FDA meeting 123
NDAC vote on switch 133
package communication of 21
safety demonstrations for 44
supplemental NDA submission 129
supporting the launch 134
timeline of 123
direct-to-OTC 31
Division of Nonprescription Drugs I (DNPD I) 34
Division of Nonprescription Drugs II (DNPD II) 34
Drug Enforcement Agency (DEA), purchase limits 32
Drug Facts label (DFL)
decision-making based on 31
Mevacor OTC “Self-Management System” 88
rule for standardized labeling 2
Durham-Humphrey Amendment 2, 5, 31

emergency contraception (EC). See Plan B (levonorgestrel) case study
emergency hormonal contraception (EHC) 172.
  See also Plan B (levonorgestrel) case study
Plan B introduction 173
reclassification of 172–178
single hormone use for 172
switch dynamics 175
Endocrine and Metabolic Drugs Advisory Committee (EMDAC) 84
enterochromaffin-like cells (ECL) 64
erective dysfunction (ED) 169
counterfeit product use 170
defined 169
OTC product utilization 169
potential value of switch 18
esomeprazole (Nexium Control) 162
ethinylestradiol/norgestrel (Schering PC4) 172
European Medicines Agency (EMA) approved switches 161
European Union/rest of world (EU)/RoW switches 161
advanced switch markets 163
EMA centralised switch approvals 161
pharmacist-only medicine requirements 162
prescription exemption mechanism 163
regulatory framework for reclassification 175
study requirements for 162
switch supply model options 163
variations in switch activity 165

F
first-in-class switch
  consideration for success of 18
  Oxytrol for women 17
Flonase 16, 21
Food and Drug Administration (FDA)
guidance for consumer use studies 9
jurisdiction for switches 34–49
  OTC labeling requirements 2
full switch. See Rx-to-OTC switch process

G
generally recognized as safe and effective (GRASE) 6, 32
general sales list (GSL) status
effect on switch in US 165
in EU/RoW 162
Germany
  for asymptomatic and chronic conditions 166
  sumatriptan approval 162
  switch process 163
ulipristal acetate vs. EHC switch 173
Gyne-Lotrimin, normalization/destigmatization of disease 14

H
H2 receptor antagonists (H2RAs)
  commercial success of 21
  Rx-to-OTC switches of 168–178
Harm Reduction Therapeutics (HRT) 44
Hatch-Waxman era 7
HIV pre-exposure prophylaxis (PrEP)
  medication 33
HRA Pharma, acutal use study in US 175

I
Imodium
  prescription vs. OTC sales 20
India, EHC market in 174
indications for switch
  consumer unmet need
    omeprazole 65
    Oxytrol 17
    Plan B 51–62
    Questran (cholestyramine) 83
  innovation in well-established category 121
  public health rationale for INS 142–159
Instructions for Use (IFU) validation 44
intranasal steroids (INS) switch 15, 137. See also allergy Rx-to-OTC switches
commercial strategies 152–159
DFL highlights 149
lifecycle management of prescription products 139
manufacturing/supply chain challenges 151–159
market volume of 16
need for 137–145
OTC launch insights 155–159
OTC market for allergy products 143,
  140–145
prescription market history 137–145
public health rationale 142–145
regulatory strategies and challenges 145
retail sales of switch products 155
strategic decision-making framework 146
Ireland, switch process 163

J
Japan
  for chronic and asymptomatic conditions 167
study requirements in 162
switch process 163
Johnson and Johnson (J&J), OTC development 87

L
label comprehension studies (LCS) 8
Differin (adapalene) Gel 125
fold-out back panel use 92
Oxytrol for Women 102
Prilosec OTC 73
Rapid assessment of adult literacy in medicine (realm) for 53
switch requirements 180
labeling
  CARE program for Plan B 59
  comprehension studies 8–11
  consumer-facing translation for switch 182
  optimizes commercial potential 180
  sample drug facts label 2
levonorgestrel. See emergency hormonal contraception (EHC)
lipid management switch
  5th Panel Self-Selection Labeling Aid 93
  Advisory Committee 2000 deliberations/outcomes 87
  category for Rx-to-OTC switch 81–98
  commercial value of switch 18
  FDA negative guidance on switch category 84
  generating stakeholder support 91–98
  in self-care environment 82
  Mevacor back panel label 90
  Mevacor system 89
  Pfizer/Lipitor (2015) 94
  praachol switch program 86
  professional treatment guidelines 82
  scientific and medical rational for 81
  statins as switch candidates
    defining target population 83
    safety topics to address 83
  statins round three at FDA 91
  switch program for Questran (cholestyramine) 82
  targeted population CUSTOM study 91
  technology-enabled labeling paradigm 93
  Lipitor (atorvastatin) 18

UK regulator 162
Merck and Co., Inc.
  CUSTOM study 87
  Nasonex switch 16
  Mevacor/Merck statin switch 84
  Advisory Committee summary for (2005) 90
  CUSTOM study for OTC development 87–98
  SELECT study (2007) 91–98
  studies supporting lovastatin switch 84
  Mevacor OTC “Self-Management System” (MOTC-SMS) 88
  Mucinex, brand equity of 20
  Multicenter Assessment of Transdermal Therapy in Overactive Bladder with Oxybutynin TDS 103

N
Nasonex (mometasone) 16
new drug application (NDA)
  efficacy supplement for switch 8
  Rx-to-OTC switches with 7
New Zealand
  contraceptive access in 174
  progressiveness in switch 165
  sildenafil switch support in 172
  switch process 163
  nicotine replacement therapies (NRT) 4, 13
  commercial value of 17
  Rx-to-OTC switch effects 17
  nicotine replacement therapy (NRT) 17
  Nonprescription Drugs Advisory Committee Oxytrol for Women 99, 106
  Nonprescription Drugs Advisory Committee (NDAC)
    FDA convened meeting of 46
    Oxytrol for Women decisions 115
    Questran (cholestyramine) 82
    switch votes of 47
  Nonprescription Drug Safe Use Regulatory Expansion (NSURE) initiative 61, 183
  Nonprescription Safe Use Regulatory Expansion (NSURE) 51
Nycomed 162

M
masking of disease concerns 75
maximal use (MuST) studies 44
MEDDEV. See guidance documents/guidelines
Medical Device Regulation (EU MDR). See EU Medical Device Regulation (EU MDR)
medical devices. See devices
medicinal products. See drugs/medicinal products
Medicines Health and Regulatory products Agency (MHRA)
  process for switch 163

198
Office of Nonprescription Drugs (ONPD)
review divisions of 34
omeprazole magnesium (Ome-Mg). See Prilosec
(omeprazole magnesium) OTC
order of entry theory
product success and 16
Orlistat (Alli, GSK in 2009) 162
OTC drug review process
monograph process failures 31
OTC Monograph Process
CARES Act reform of 32
GRAS/E concept in switches 6–11
overactive bladder (OAB) 99. See Oxytrol for Women
over-the-counter (OTC) drugs/medicines
accessibility of allergy medicines 183
benefits of
access 3
affordability 4
consumer education 14
cost-effectiveness of 14
empowerment and trust 5
for consumer usage 5
characteristics 33
consumer and healthcare system affordability 184
consumer trust of 184
creation of new categories 5
defined 1–11
first-in-class switch challenges 77
historical eras of 31
1950s–early 1970s 6–11
1970–1980s 6–11
1984–Today 7
IRI value study on 4
Nonprescription Safe Use Regulatory
Expansion 10
safety/efficacy requirements 2
sample drug facts label 2
oxybutynin. See Oxytrol for Women
oxybutynin transdermal system 17, 99
Oxytrol for Women
actual use studies
adjudication process (mitigation) 108
combined endpoint analysis 112
control 107–108
description of subjects 109–115
primary endpoint 108
primary endpoint analysis 110–115
recruitment 107–108
recruitment and enrollment 109
secondary endpoint analysis 110–115
secondary endpoints 108
Advisory Committee meeting
description of subjects 115–117
commercial failure of 20
CONTROL study 112–115
allergic reactions 114
anticholinergic effects 114
bladder cancer risk factors 114
common adverse events 112–115
conclusions from 115
deaths and discontinuations 112
disorientation and confusion 115
falls and accidents 115
gastric retention and glaucoma risks 114
possible urinary tract infection symptoms 113
risk factors for diabetes 114
serious adverse events 112
urinary retention 113
Drug Facts Label development 118
benefit-risk assessment 118
eyear consumer testing 100–101
end of Phase 2 meeting 102
indications for switch 99–101
label comprehension studies
diabetes warnings 104
enhanced pregnancy warning 103
full label comprehension 104
pivotal comprehension study 104
safety and risk communication 101
self-diagnosis/selection 101
pre-IND meeting for 99–101
pre-NDA meeting and filing 115–117
prescription market size 17
self-selection studies
targeted, in pregnant women 106
targeted self-selection (men) 106
stage 2 consumer studies 103
Pantazole 162
pantoprazole 162
partial switch
prescription product availability 35
sponsior decision on 8
PDE5 inhibitors. See erectile dysfunction (ED)
Peck’s Principles 7
Pepcid 20
Plan B. See also emergency hormonal contraception (EHC)
Plan B (levonorgestrel) case study 51, 172
advance provision studies for 56
Advisory Committee meeting 55
AUS study 54–62
customer unmet need 51
educational program for 59
empowering of women 14
full access battle for 59
label comprehension results by age 53
label comprehension study 53
other behavioral studies for 55–62
Plan B One-Step approval 60
political influence in approval 58–62
public policy/advocacy 52–62
quest for Plan B One-Step OTC approval 60–62
reasons for non-approval 55–62
regulatory history of 52–62
survey summary for 58
Poland
restriction of EHC in 173
reversal of switch 162
sildenafil switch in 171
Pravachol/BMS (2000) statin switch 84
studies supporting pravastatin switch 86
prescription medicines
allergy brands launched by switch 17
to nonprescription status 1
Prevacid
prescription vs. OTC sales 19
spending to build awareness 20
Prilosec (omeprazole magnesium) OTC
Black Box warning 66
building awareness for 19
case study
actual use trial 74
consumers with infrequent heartburn 74
FDA concerns 72
label comprehension study 73
second Advisory Committee meeting 75
consideration in switch
Black Box warning 65–80
considerations for switch 65
Category C for pregnancy 67
dosage form 66–80
minimum effective dose 67
drug-induced hypergastrinemia 75
FDA concerns
brand name confusion 77
comments 71, 74
first Advisory Committee meeting 71
prevention or treatment of heartburn 76
product sampling during launch 77
time to action concerns 76
yearly courses of therapy 76
frequency of switches in 1998–2000 64
genotoxicity and tumororigenicity concerns 75
H2RAs and omeprazole mechanisms of action 65
heartburn prevention studies 69, 68–80, 70, 72
heartburn treatment studies 68
history of switch 63
length of treatment concerns 75
proposed indications and development plan 68
state of switch in 2000 63–80
unique mechanism of 64
unmet consumer need 63–80
principal display panel (PDP) for communication 21
proton pump inhibitors (PPIs)
brands launched by switch 19
prescription vs. nonprescription indications 19
Prilosec OTC case study 63–80
purchase decision 92
R
Rapid Assessment of Adult Literacy in Medicine (REALM)
in self-selection studies 129
label comprehension studies 53
real-world data use 162
rest of the world (RoW) switches 161
reverse switches 161
Rhinocort brand awareness in switch 19
Rx-to-OTC switch
criteria for switch 183
Rx-to-OTC switch process 1. See also approval pathways for switch
approval if benefits outweigh risks 47
as lifecycle management strategy 14, 179
assessing category dynamics 17
assessing the value of
ability to execute at retail 24–29
high performing team 25–29
strategy implications for 25
barriers and enablers to switches 16, 165
benefits of 13–29
branded vs. private label sales 18
business models for 26
case history of H2RAs 169
commercial success of 14
comparison of enablers and barriers 167
elapsed approval times 46
emergency hormonal contraception 172–178
enhanced DFL warning 42
entry order vs current sales rank 23
erectile dysfunction case study 169–178
evaluating the value of candidates for 13
FDA guidance for sponsor studies 45–49
FDA input on proposed development 45–49
FDA input on proposed NDA 45–49
FDA jurisdiction for 34–49
first-in-class switch 77
for asymptomatic and chronic conditions 166–178
frequency in 1998–2000 64
full vs. partial switches 8, 34–49, 35–49
innovation in an established category 121
in US 31
issues for successful switch program 181–185
lipid management in the US 81
Lotrimin Ultra Pictogram 38
medicines for chronic and prophylactic use 166
models for self-selection tests 183
naming approaches used in 41
OTC Naloxone DFL created by FDA 40
Oxytrol for Women 99
partnerships for 26
PERT/PERS charts for 182
philosophy of 32–49
potential switch supply models 164
pricing premiums for waves of innovation 22
principles for switch candidates 7
proposed development plan 39–49
retail sales of branded 20
sponsor creates DFL 36
sponsor decision on 8
sponsor files NDA with PDUFA timing 46–49
studies and parameters measured 36
therapeutic categories (2020) 16
therapeutic categories for 6
tools for evaluation of 181
value tree method for benefit assessment 33
Voltaren Arthritis Pain Outer Carton 39
Voltaren Arthritis Pain Pictogram 39
Rx-to-OTC switch value
ability to innovate 23–29
Advil products approved by NDA 23
allergy brands and retail sales 17
allergy treatments 15
branded vs. private label smoking cessation
products 18
brands launched via switch 15
building awareness for 19–29
building equity 19
category size 14–29
derential order effects on 22–29
evaluating the candidate 13
factors in commercial success
brand equity 19
ease of use 21
pricing on new products 22
spending to build awareness 20
unmet consumer needs 21
media spends for 20
new innovation pricing 22
NSAs vs. INSs retail sales 18
order of entry effects 23
PPI brands launched as result of switch 19
prescription and consumer health business
models 26
side effects and repeat use 22
therapeutic categories in retail sales 16
volume sources for recent switches 17
Rx-to-OTC switch value
consumer awareness 19

S
Scandinavian Simvastatin Survival Study 83
science of switch 8
SELECT study
purchase decision (PD) 92
self-assessment (SA) decision 92
self-care environment. See also self-management
effects of COVID-19 on 10
evolution of 1
lipid management switch 82
self-care pyramid 3
Self-Diagnosis/Self-Selection Study Oxytrol for Women 101
Self-Evaluation of Lovastatin to Enhance Cholesterol Treatment (SELECT) 92
self-management. See also self-care environment acne 122
decisions for lipid management 92–94
for cholesterol treatment 92
for lipids/cholesterol 81
technology as tool for 183
self-selection studies (SSS) 8
Differin Gel (adapalene) switch 128
Differin Gel OTC package warning 129
for Oxytrol 101
Oxytrol in pregnant women 106
Oxytrol label warning for men 106
Serious Adverse Events (SAEs), Oxytrol for Women 112
sildenafil. See also erectile dysfunction (ED)
barriers to access of 170
centralized switch of 171
in European market 170
overall utilization of 169
single shelf keeping unit (SKU) vs. “billboard” 23
Somac 162
sumatriptan
   EU/Row switch 162
   UK switch 165
Sweden, influences on switch 166

T
Tagamet 20, 21

U
Ulipristal acetate 30mg (ellaOne, HRA Pharma) 162
under the counter (UTC) purchases 162
United Kingdom (UK)
   contraceptive advertising in 174
desogestrel (DSG) prescription in 174
emergency hormonal contraceptive licensed in 172
   prescription and nonprescription schedules in 163
   reclassification for access 163, 165
Zocor (simvastatin) switch 18

V
Viagra 169. See sildenafil

W
World Health Organization (WHO), criteria for contraceptive access 174

Z
Zantac 20
Zegerid brand equity at switch 19